3 news items
Cogent Biosciences Reports First Quarter 2024 Financial Results
COGT
7 May 24
Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company's clinical development plans and timelines
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
COGT
26 Feb 24
forward-looking statements within the meaning of the Private Securities Litigation Reform
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
COGT
22 Feb 24
release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
- Prev
- 1
- Next